CD40 ligand, Bcl-2, and Bcl-xL spare group I Burkitt lymphoma cells from CD77-directed killing via Verotoxin-1 B chain but fail to protect against the holotoxin

Απλή σελίδα τεκμηρίου
dc.contributor.authorGordon, J.en
dc.contributor.authorChalla, A.en
dc.contributor.authorLevens, J. M.en
dc.contributor.authorGregory, C. D.en
dc.contributor.authorWilliams, J. M.en
dc.contributor.authorArmitage, R. J.en
dc.contributor.authorCook, J. P.en
dc.contributor.authorRoberts, L. M.en
dc.contributor.authorLord, J. M.en
dc.date.accessioned2015-11-24T19:31:24Z
dc.date.available2015-11-24T19:31:24Z
dc.identifier.issn1350-9047-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23260
dc.rightsDefault Licence-
dc.subjectAntibodies, Monoclonal/pharmacologyen
dc.subjectB-Lymphocytes/drug effects/*metabolismen
dc.subjectBurkitt Lymphoma/drug therapy/*metabolism/pathologyen
dc.subjectCD40 Ligand/*metabolism/pharmacologyen
dc.subjectCell Deathen
dc.subjectCell Lineen
dc.subjectDNA/metabolismen
dc.subjectEscherichia coli/metabolismen
dc.subjectHumansen
dc.subjectIonomycin/pharmacologyen
dc.subjectProtein Subunitsen
dc.subjectProto-Oncogene Proteins c-bcl-2/genetics/*metabolismen
dc.subjectReceptors, Cell Surface/*metabolismen
dc.subjectShiga Toxin 1/metabolism/*pharmacology/therapeutic useen
dc.subjectSignal Transductionen
dc.subjectTrihexosylceramides/*metabolismen
dc.subjectbcl-X Proteinen
dc.titleCD40 ligand, Bcl-2, and Bcl-xL spare group I Burkitt lymphoma cells from CD77-directed killing via Verotoxin-1 B chain but fail to protect against the holotoxinen
heal.abstractOwing to its lineage and differentiation stage-restricted expression, CD77 has been mooted as a therapeutic target in Burkitt lymphoma (BL). The recognition that the globotriaosyl moiety of this neutral glycosphingolipid is a receptor for Escherichia coli-derived Verotoxin-1 (Shiga-Like Toxin-1) offers a potential delivery system for the attack. Here we show that CD77-expressing Group I BL cells which are normally susceptible to activation-induced death on binding Verotoxin-1 B chain are protected in the presence of CD40 ligand. Ectopic expression of either bcl-2 or bcl-xL also afforded resistance to the actions of the B chain. In total contrast, neither of the survival genes nor a CD40 signal - even when acting in concert - protected against killing mediated by the holotoxin. These findings indicate that while therapeutic modalities for CD77-expressing B cell tumors (which include follicular lymphoma) based on the use of Verotoxin-1 B chain might be compromised by the activation of endogenous or exogenous survival pathways, those exploiting the holotoxin should be left unscathed.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1038/sj.cdd.4400710-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/11042673-
heal.identifier.secondaryhttp://www.nature.com/cdd/journal/v7/n9/pdf/4400710a.pdf-
heal.journalNameCell Death Differen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2000-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ